Memorial Sloan Kettering Cancer Center is a cancer treatment and research institution in the borough of Manhattan in New York City, founded in 1884 as the New York Cancer Hospital.

There are 498 (2018) beds in Memorial Sloan Kettering Cancer Center (All Protocol Activities).

During the past decade, Memorial Sloan Kettering Cancer Center (All Protocol Activities) conducted 127 clinical trials. In the 10-year time frame, 127 clinical trials started and 9 clinical trials were completed, i.e. on average, 7.1% percent of trials that started reached the finish line to date. In the past 5 years, 111 clinical trials started and 6 clinical trials were completed. i.e. 5.4% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Memorial Sloan Kettering Cancer Center (All Protocol Activities)" #1 sponsor was "Memorial Sloan Kettering Cancer Center" with 137 trials, followed by "National Institute of Allergy and Infectious Diseases (NIAID)" with 8 trials sponsored, "Pfizer" with 2 trials sponsored, "BioMérieux" with 1 trials sponsored and "Genmab" with 1 trials sponsored. Other sponsors include -3 different institutions and companies that sponsored additional 7 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Memorial Sloan Kettering Cancer Center (All Protocol Activities)" #1 collaborator was "Genentech, Inc." with 4 trials as a collaborator, "Merck Sharp & Dohme LLC" with 4 trials as a collaborator, "AstraZeneca" with 3 trials as a collaborator, "Bristol-Myers Squibb" with 3 trials as a collaborator and "Amgen" with 2 trials as a collaborator. Other collaborators include 70 different institutions and companies that were collaborators in the rest 76 trials.

According to Clinical.Site data, the most researched conditions in "Memorial Sloan Kettering Cancer Center (All Protocol Activities)" are "Breast Cancer" (14 trials), "HIV Infections" (8 trials), "Multiple Myeloma" (6 trials), "Prostate Cancer" (6 trials) and "Ovarian Cancer" (5 trials). Many other conditions were trialed in "Memorial Sloan Kettering Cancer Center (All Protocol Activities)" in a lesser frequency.

Most popular intervention types in "Memorial Sloan Kettering Cancer Center (All Protocol Activities)" are "Drug" (85 trials), "Other" (24 trials), "Radiation" (21 trials), "Procedure" (18 trials) and "Diagnostic Test" (16 trials). Other intervention types were less common.

The name of intervention was led by "Nivolumab" (8 trials), "Pembrolizumab" (7 trials), "Cisplatin" (5 trials), "Gemcitabine" (5 trials) and "Placebo" (5 trials). Other intervention names were less common.

The vast majority of trials in "Memorial Sloan Kettering Cancer Center (All Protocol Activities)" are 130 trials for "All" genders, 15 trials for "Female" genders and 6 trials for "Male" genders.

Currently, there are NaN active trials in "Memorial Sloan Kettering Cancer Center (All Protocol Activities)". 1 are not yet recruiting, 92 are recruiting, 27 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 23 completed trials in Memorial Sloan Kettering Cancer Center (All Protocol Activities), undefined suspended trials, and 5 terminated clinical trials to date.

Out of the total trials that were conducted in Memorial Sloan Kettering Cancer Center (All Protocol Activities), 31 "Phase 1" clinical trials were conducted, 74 "Phase 2" clinical trials and 9 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 2 trials, and there were also 19 trials that are defined as “Not Applicable".